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Purpose. To evaluate the diagnosis value of integrated positron emission tomography and computed tomography (PET/CT) with
lung masses, this study emphasized the correlation between tumor size and maximum standardized uptake value (SUVmax) in
selected regions of interest (ROI) of lung masses. Material and Methods. A retrospective analysis was performed on 85 patients
with solid pulmonary lesions, all veriﬁed by pathology. The morphology, edge (speculated margins and lobule), size, density of
pulmonary masses, and on-chest CT images were reviewed. The SUVmax in ROI of pulmonary masses was calculated. Results.
Among the 85 patients with lung masses, 59 patients presented with pulmonary malignant neoplasm and 26 patients with benign
lesions.Thesensitivity,speciﬁcity,andaccuracywere89.8%,61.5%,81.2%,respectively,forPETmeasurementonly,88.1%,65.4%,
81.2% for CT only, and 96.6%, 80.8%, 91.8% for PET/CT. The size of pulmonary malignant neoplasm in the 59 patients was
apparently correlated with the ROI’s SUVmax (r = 0.617, P<. 001). However, the size of pulmonary benign mass in the 26
patients was not correlated with the SUVmax. Conclusion. PET/CT is of greater value in characterization of lung masses than
PET and CT performed separately. The examination of lung tumor can be further speciﬁed by the correlation between the size of
pulmonary malignant neoplasm and the ROI’s SUVmax.
Copyright © 2007 Guangming Lu et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. THE ADVANTAGE OF PET AND CT INTEGRATION IN
EXAMINATION OF LUNG TUMORS
In recent years, the incidence and mortality of lung cancer
are always ranked as the highest among all neoplasms. Mass
istheprincipalmanifestationoflungcancer,whosediagnosis
is of vital clinical signiﬁcance [1–5]. Early and accurate diag-
nosis of lung cancer is critical to its therapy. PET/CT com-
bines the merits of both functional and anatomical imaging
techniques and has been widely used in clinical examination,
with a hope to make the diagnosis of neoplasm as early as
possible. The current study evaluated the diagnosis value of
PET/CT.
2. MATERIAL AND METHODS
2.1. Imagingacquisition
Fluorine-18-labeled ﬂuorodeoxyglucose (18F-FDG) was
produced by EBCO cyclotron facility. Radiochemical purity
(>95%) of 18F-FDG was veriﬁed by analytical HPLC. All pa-
tients fasted for at least 6 hours before PET/CT examination.
After ensuring a normal peripheral blood glucose level, pa-
tientsreceivedanintravenousinjectionof0.2mCi/kgof18F-
FDG, and then rested for approximately 50–60 minutes be-
fore undergoing a PET/CT scan. Image acquisition was per-
formed using an integrated PET/CT device (Siemens Bio-
graph Sensation 16). CT was performed from the head to
thepelvicﬂoorusingastandardizedprotocol(120KV,80mA
with a slice thickness of 5mm). PET images in early display
were acquired using 3D mode for the same scanning range
as CT. The acquisition time for PET was 3 minutes per bed
position and 5-6 continuous positions were scanned. De-
layed images of chest were acquired at 3 hours after injec-
tion of 18F-FDG. The acquisition parameters of the two PET
scans are the same. PET images datasets were reconstructed
iteratively using an ordered subset expectation maximization
algorithm and corrected with measured attenuation correc-
tion. The SUVmax of the selected ROI in lesions was calcu-
lated.CT,PET,andPET/CTinfusionimagesofaxial,sagittal,
and coronal images were obtained through a postprocessing
procedure.
2.2. Patientdata
85 patients (54 males, 31 females; age range: 36–87 years;
mean age: 58 years) with lung masses were enrolled in this2 International Journal of Biomedical Imaging
Table 1: The diagnostic value of PET only, CT only, and integrated PET/CT on 85 patients with lung masses.
Methods Sensitivity (%) Speciﬁcity (%) Positive predictive value (%) Negative predictive value (%) Accuracy (%)
PET only 89.8 (53/59) 61.5 (16/26) 84.1 (53/63) 72.7 (16/22) 81.2 (69/85)
CT only 88.1 (52/59) 65.4 (17/26) 85.2 (52/61) 70.8 (17/24) 81.2 (69/85)
Integrated PET/CT 96.6 (57/59) 80.8 (21/26) 91.9 (57/62) 91.3 (21/23) 91.8 (78/85)
See Figures 3(a)–5(c) for further demonstration of our cases.
study. Each patient received the early 18-FDG scan described
above. 70 patients underwent a second delayed scan because
either their pulmonary masses could not be determined or
they had suspected pulmonary malignancies. Other 15 pa-
tients did not undergo delayed 18F-FDG scan because they
already had a deﬁnite diagnosis based on CT and/or early
PET scan.
2.3. Dataanalysisandprocessing
2.3.1. SemiautomaticquantiﬁcationofROI
ROI was drawn on the slice that showed clearly radioactivity
aggregation. For an early scan, the SUVmax over 2.5 was re-
garded as positive; and for a delayed scan, the SUVmax over
2.5 or with10% increase compared to the early scan, was rec-
ognized as positive. CT images were mainly employed to ex-
amine the morphology, edge (i.e., speculated margins and
lobulation), size, and density of pulmonary lesions. Metas-
tasis derived from PET or CT was comprehensively analyzed
with other clinical proﬁles. If a lung mass was irregular in its
shape and/or its edge was poorly deﬁned such as being spic-
ulated, having radiating corona, umbilicated, or lobulated
without benign signs of lung masses (e.g., having character-
istic calciﬁcation or fat), it was regarded as malignant neo-
plasm. The images were interpreted by two experienced radi-
ologists who had obtained a position higher than the rank of
attending physicians. Diagnosis was determined only when
a consensus was achieved. If no consensus was achieved, it
would be subject to further review by the whole department.
The diagnostic sensitivity, speciﬁcity, and accuracy of PET
only, CT only, and PET/CT were analyzed. The correlations
between tumor sizes and ROI’s SUVmax were quantitatively
compared.
2.4. Statistics
The correlations between tumor sizes and metabolism of
the lesions were performed using an SPSS software (version
11.5). Pearson correlation was calculated with P<. 05 or
P<. 001, considered as a standard of signiﬁcance level or
a very signiﬁcant diﬀerence, respectively.
3. RESULTS
Therewere85patientswithsolidpulmonarylesions:59cases
of malignant neoplasms, 26 cases of benign masses. Among
the malignant neoplasm cases, there were 19 squamocellu-
lar carcinomas, 25 adenocarcinomas, 3 alveolar cell carci-
nomas, 4 small-cell nondiﬀerentiated adenocarcinomas, 1
eosinophilic cell carcinoid, 1 adenospuamous carcinoma, 2
dual-origin carcinomas (one right and left upper lung cav-
ernous squamocellular carcinoma and one left upper lung
adenocarcinoma with right lower lung mixed carcinoma),
and 4 metastases. Among the benign mass cases, there were 9
lungtuberculoses,7inﬂammatorygranulomatosis,3chronic
inﬂammations, 2 acute inﬂammations, 1 round ateletasia, 1
fungus, and 3 other benign tumors. The diagnostic values of
PET only, CT only, and PET/CT for these lung masses were
shown in Table 1 and Figures 3(a)–5(a). There were 10 false
positive cases and 6 false negative cases (5 neoplasms with a
diameterlowerthan1cmandonehighlydiﬀerentiatedcarci-
noid) for PET-only imaging. 9 false positive cases and 7 false
negative cases would have been found if CT-only scan was
employed. The numbers of both false positive cases (5 cases)
and false negative cases (2 cases) for integrated PET/CT were
smaller than those for PET alone or CT alone (see Table 1
and Figures 3–5).
Figures 1 and 2 illustrate the correlations between 18F-
FDGuptakeandthetumorsizes.Theresultsfromastatistical
analysis showed that while the sizes of pulmonary malignant
tumors were signiﬁcantly correlated with the ROI’s SUVmax
(r = 0.617, P<. 001), there was no signiﬁcant correlation
between the ROI’s SUVmax and the sizes of masses in benign
lesions measured on PET/CT.
4. DISCUSSION
Lung masses might be classiﬁed when they are larger than
3cm and less than 3cm in diameter. Among the solitary pul-
monary nodules with a diameter less than 3cm, there were
33%malignantnodules,54%inﬂammatorygranulomatoses,
6% hamartomas, 5% isolated metastases, and 2% bronchial
adenomas [3–7]. Most lung masses with a diameter larger
than 3cm were malignant [4]. To resolve diﬀerential diag-
noses of lung masses based on the diﬀerent types of scans
still remains a challenge to radiologists.
4.1. ThediagnosticvalueofPETaloneforlungmass
The extent of 18F-FDG uptake can be a good reference to
the property of a certain mass. The absorbances of FDG in
malignant neoplasms were signiﬁcantly higher than those
of benign tumors. Most radiologists employed the semiau-
tomatic quantiﬁcation of SUVmax, with 2.5 as a thresh-
old value [1, 2, 8, 9]. Tumors with SUVmax >2.5 were
classiﬁed as malignant lesions. End-stage pulmonary carci-
noma can be accompanied with high metabolism metas-
tasis to pulmonary hilar lymph nodes, mediastinal lymph
nodes, and other organs [9, 10]. By applying this standard,Guangming Lu et al. 3
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Figure 1: The correlation between FDG uptake and the sizes of 59
malignant tumors.
the diagnostic sensitivity, speciﬁcity, and accuracy are about
89.8%, 61.5%, and 81.2%, respectively. Dewan et al. [11]r e -
ported that the diagnostic sensitivity, speciﬁcity, and accu-
racy of PET for lung nodules were 95%, 87%, and 92%, re-
spectively. In 1474 cases with solitary pulmonary nodules,
the 18F-FDG PET had a diagnostic sensitivity of 96.8% and
a speciﬁcity of 77.8% [12]. While discrepancy exists between
our work and other reports, false positivity and false nega-
tivity exist in all groups. Tuberculosis, inﬂammatory pseu-
dotumor, aspergillosis, and granulomatosis can also have an
uptake of FDG and lead to false positivity. In our cases, there
were 10 false positive cases, which had a lower positive pre-
dictive value of 85.2% for PET. Among the 6 false negativi-
ties, 5 were small lung cancer (diameter <10mm), which im-
plies that the threshold of SUVmax 2.5 needs to be modiﬁed
for the diagnosis of small lung cancer with PET. In addition,
dual-time-point 18F-FDG PET is necessary in order to im-
prove the accuracy of diagnosis.
4.2. DiagnosisoflungmasswithCT
CT scan was used to analyze the characteristics of lesions in-
volving the location, morphology, edge (i.e., speculated mar-
gins and lobule), size, density, and enhancement manifesta-
tions after injecting contrast agent. Small lung nodules re-
quire a thin-slice CT scan protocol and/or dynamic enhance-
ment. Although spiral CT could aﬀord more detailed infor-
mation such as intranodular calciﬁcation and blood supply
of the mass, it still lacks speciﬁcity for certain lung nodules.
Our results showed that the sensitivity, speciﬁcity, and accu-
racy of CT in the diagnosis are 88.1%, 65.4%, and 81.2%,
respectively. Yi et al. [13] reported that the diagnostic sensi-
tivity, speciﬁcity, and accuracy of lung malignant neoplasm
with dynamic enhanced spiral CT are 81%, 93%, and 85%,
respectively. Though its diagnostic value improved some-
what, there is still some diﬃculty in evaluating their cases.
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Figure 2: The correlation between FDG uptake and the sizes of 26
benign masses.
There were 9 false positive cases and 7 false negative cases in
our CT series. The reason for this diﬀerence might be that
the ﬁndings based on pathologies could have a similar CT
manifestation while the same pathology might have diﬀerent
images. Therefore, to improve the diagnostic accuracy, other
diagnostic procedures need to be integrated with CT mea-
surements.
4.3. Thecorrelationoflungmasssizeand
itsmetabolism
This research showed that there was a positive correlation
between the size of malignant tumor and PET/CT SUVmax
(r = 0.617,P<. 001).InFigure 1,thereisalinearcorrelation
betweenthemalignanttumorsizeandSUVmax.Notonlytu-
mor size but also the focal metabolism should be taken into
account in the diagnosis of malignant tumors with PET/CT.
Especially for those with an SUVmax <2.5, lung carcinoma
could not be excluded. False negativity might arise from the
following reasons [6, 7, 9, 14–17].
(1) Some types of tumors, for example, bronchial alve-
olar cell carcinoma, carcinoid, and well-diﬀerentiated ade-
nocarcinoma, might have a reduced metabolism, and a false
negativity.
(2)Tumorssmallerindiameter(<10mm)havealowSU-
Vmax, and they might produce partial volume eﬀect.
(3) There are a large number of ﬁbers inside the tumors
a n dal o wq u a n t i t yo ft u m o rc e l l s .
(4) The patients had high blood glucose level.
Most false negativities in our series were at small foci.
Great caution should be taken for the diagnostic small nod-
ules with a diameter <10mm since such small malignancies
might have an SUVmax <2.5. Diﬀerent criteria are needed to
determine malignancy in nodules less than 10mm in diam-
eter. As shown in Figure 2, there is no correlation between
the size of benign lesions and SUVmax of PET/CT. This may4 International Journal of Biomedical Imaging
(a) (b) (c)
Figure 3: (a), (b), and (c) were from the same patient. The pathological diagnosis is right upper pulmonary squamous carcinoma. There
were typical manifestations on CT, PET, and integrated PET/CT. The mass on CT is 2.4cm× 2.5cm. The SUVmax of early PET imaging is
7.8.
(a) (b) (c)
Figure 4: (a),(b),and (c)were from thesame patient. Thepathological diagnosis is leftupper lungadenocarcinoma. OnCT,asmall module
(0.9cm×1.0cm) with lobulation and speculated margin was seen in the left upper lung (a). No typical manifestation was seen on PET. The
SUVmax of early PET imaging was 1.9 (b). Integrated PET/CT suggested suspected lung carcinoma (c).
reﬂect the complexity of tumor metabolism, suggesting that
the masses are not proportional to SUVmax of PET/CT. If a
focus has an SUVmax >2.5, but the size of the mass is not
in accordance with the SUVmax, caution should be taken to
avoid false positivity. Bunyaviroch et al. [6, 7, 9, 10, 17]r e -
ported that false positivity in imaging might arise in tuber-
culosis, sarcoidosis, histoplasmosis, aspergillosis, and pleural
mesothelioma.
4.4. DiagnosticvalueofintegratedPET/CT
forlungtumor
The diagnostic procedure of integrated PET/CT for lung
masses was as follows.
(1) The metabolism of FDG should follow the standard
for malignant tumors from the view of PET.
(2) Lung tumors should follow the standard of CT con-
cerning the density, morphology, edge, and enhancement.
When either of the standards was met, lung tumor
could be diagnosed. When only one of the requirements
was achieved, caution should be taken. Further, inspec-
tion should pursue. When neither of the requirements was
reached, lung tumor could be excluded. Yi et al. [13, 16]r e -
ported that the diagnostic sensitivity, speciﬁcity, and accu-
racy of integrated PET/CT for lung malignancy were 96%,
88%, and 93%, respectively, but 96.6%, 80.8%, and 91.8%
in our series. Winer-Muram et al. [16, 18] reported that
as compared with CT, PET/CT provided additional infor-
mation, including more accurate location, diﬀerentiation
of pathological and physiological uptakes, pickup of foci
omitted by CT. The results from the current study showed
that integrated PET/CT had higher sensitivity and speciﬁcity
than CT or PET when performed separately, indicating that
PET/CT may play a more important role in lung tumor di-
agnosis. Given the false positivity and false negativity de-
tected, PET/CT may not be ideally speciﬁc for lung tumor
[13, 15, 16, 18]. We ought to combine the information of
focal metabolism, morphology, volume, and density in or-
der to avoid false positivity and false negativity. To meet such
need, the usage of diﬀerent tracers, needle biopsy, or follow-
up should be pursued to ensure accurate diagnosis.
5. CONCLUSION
The integration of PET and CT is of greater value for the
diagnosis of lung masses than other methods using PET orGuangming Lu et al. 5
(a) (b) (c)
Figure 5: (a), (b), and (c) were from the same patient. The pathology is left lung inﬂammation. A big mass (5.3cm×5.7cm) with lobulation
and spurring was seen on CT (a). Malignant tumor was suspected on CT. False positivity was seen on PET; its early imaging SUVmax is 6.6
(b). The integrated PET/CT also suggested possible lung carcinoma (c).
CT alone. Our results showed that the size of pulmonary
malignant neoplasms was correlated with ROI’s SUVmax of
PET/CT positively, but the size of pulmonary benign lesion
wasnotcorrelatedwiththeSUVmax.Theseﬁndingsindicate
that PET/CT may enhance the sensitivity, speciﬁcity, and ac-
curacy of diagnosis on lung tumors.
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